Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study.
作者信息
Hamlin Paul A, Flinn Ian W, Wagner-Johnston Nina, Burger Jan A, Coffey Greg P, Conley Pamela B, Michelson Glenn, Leeds Janet M, Der Kenneth, Kim Yvonne, Sabalvaro-Torres Alice, Birrell Matt, Pandey Anjali, Curnutte John T, Patel Manish R
机构信息
Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Medicine, Weill Cornell Medical College, New York, New York.
出版信息
Am J Hematol. 2019 Apr;94(4):E90-E93. doi: 10.1002/ajh.25387. Epub 2019 Jan 8.
PMID:30592080
Abstract
摘要
Zotero 插件